RAPP — Rapport Therapeutics Share Price
0.000.00%
Last trade - 00:00- $413.52m
- $108.24m
- 43
- 32
- 27
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.35 | ||
| Price to Tang. Book | 1.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.13% | ||
| Return on Equity | -55.97% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 10th, 2022
- Public Since
- June 7th, 2024
- No. of Shareholders
- 50
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 36,497,555
- Address
- 1325 Boylston Street, Suite 401, BOSTON, 02215
- Web
- https://www.rapportrx.com/
- Phone
- +1 8573218020
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for RAPP
Rapport Therapeutics Inc At Mizuho Neuro and Ophthalmology Summit
Rapport Therapeutics Inc Annual Shareholders Meeting
Similar to RAPP
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Rapport Therapeutics share price?
As of Today at 22:52 UTC, shares in Rapport Therapeutics are trading at $11.33. This share price information is delayed by 15 minutes.
How has the Rapport Therapeutics share price performed this year?
Shares in Rapport Therapeutics last closed at $11.33 and the price had moved by over the past 365 days. In terms of relative price strength the Rapport Therapeutics share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Rapport Therapeutics?
The overall consensus recommendation for Rapport Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rapport Therapeutics dividend yield?
Rapport Therapeutics does not currently pay a dividend.
Does Rapport Therapeutics pay a dividend?
Rapport Therapeutics does not currently pay a dividend.
When does Rapport Therapeutics next pay dividends?
Rapport Therapeutics does not currently pay a dividend.
How do I buy Rapport Therapeutics shares?
To buy shares in Rapport Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rapport Therapeutics?
As of the previous close price of $11.33, shares in Rapport Therapeutics had a market capitalisation of $413.52m.
Where are Rapport Therapeutics shares listed?
Here are the trading details for Rapport Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RAPP
What kind of share is Rapport Therapeutics?
Based on an overall assessment of its quality, value and momentum Rapport Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rapport Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Rapport Therapeutics is $35.00. That is 208.91% above the last closing price of $11.33.
Analysts covering Rapport Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.48 for the next financial year.
Find out moreWhat is the trend in the Rapport Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rapport Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -53.77%.
As of the last closing price of $11.33, shares in Rapport Therapeutics were trading -35.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rapport Therapeutics PE Ratio?
The Rapport Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rapport Therapeutics?
We do not have data on Rapport Therapeutics' directors